924473-59-6
924473-59-6 structure
- Name: T 5601640
- Chemical Name: 3-Methyl-N-(3-{[3-(trifluoromethyl)phenyl]carbamoyl}phenyl)-1,2-oxazole-5-carboxamide
- CAS Number: 924473-59-6
- Molecular Formula: C19H14F3N3O3
- Molecular Weight: 389.328
- Catalog: Signaling Pathways Cell Cycle/DNA Damage LIM Kinase (LIMK)
- Create Date: 2018-05-10 16:21:29
- Modify Date: 2025-08-24 15:06:32
-
T56-LIMKi is a selective inhibitor of LIMK2; inhibits the growth of Panc-1 cells with an IC50 of 35.2 μM.
| Name | 3-Methyl-N-(3-{[3-(trifluoromethyl)phenyl]carbamoyl}phenyl)-1,2-oxazole-5-carboxamide |
|---|---|
| Synonyms |
3-Methyl-N-(3-{[3-(trifluoromethyl)phenyl]carbamoyl}phenyl)-1,2-oxazole-5-carboxamide
5-Isoxazolecarboxamide, 3-methyl-N-[3-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]- T-5601640 T56-LIMKi |
| Description | T56-LIMKi is a selective inhibitor of LIMK2; inhibits the growth of Panc-1 cells with an IC50 of 35.2 μM. |
|---|---|
| Related Catalog | |
| Target |
LIMK2 |
| In Vitro | T56-LIMKi efficiently inhibits the growth of ST88-14, U87, Panc-1 cells, A549 lung cancer cells with IC50 values of 18.3, 7.4, 35.2 and 90 μM, respectively. T56-LIMKi decreases phosphorylated cofilin (p-cofilin) levels and thus inhibits growth of several cancerous cell lines, including those of pancreatic cancer, glioma and schwannoma[1]. It blocks the phosphorylation of cofilin which leads to actin severance and inhibition of tumor cell migration, tumor cell growth, and anchorage-independent colony formation in soft agar. T56-LIMKi (10-50 μM) reduces p-cofilin in a dose-dependent manner in NF1−/−MEFs with an IC50 of 30 μM. Notably, the inhibitor does not affect the amounts of total cofil. 50μM T56-LIMKi causes a statistically significant reduction in the number of cells exhibiting stress fibers[2]. |
| In Vivo | T56-LIMKi can induce inhibition of cofilin phosphorylation and Panc-1 tumor shrinkage in vivo. Mice treated with T56-LIMKi (60 mg/kg) shows a significant decrease in tumor volume compared to control[1]. |
| Cell Assay | T56-LIMKi can induce inhibition of cofilin phosphorylation and Panc-1 tumor shrinkage in vivo. Mice treated with T56-LIMKi (60 mg/kg) shows a significant decrease in tumor volume compared to control[1]. |
| Animal Admin | Mice: T56-LIMKi is dissolved in 0.5% carboxymethylcellulose solution. Mice are implanted with xenografted Panc-1 cells. Treatment is started 7 days later. Mice in the two experimental groups are each treated with a daily oral non-toxic dose of T56-LIMKi (30 or 60 mg/kg in gavage) and mice in the control group receives only the vehicle (0.5% CMC) in the gavage[1]. |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 403.4±45.0 °C at 760 mmHg |
| Molecular Formula | C19H14F3N3O3 |
| Molecular Weight | 389.328 |
| Flash Point | 197.8±28.7 °C |
| Exact Mass | 389.098724 |
| LogP | 2.85 |
| Vapour Pressure | 0.0±0.9 mmHg at 25°C |
| Index of Refraction | 1.618 |
| Symbol |
GHS06 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H301-H413 |
| Precautionary Statements | P301 + P310 + P330 |
| RIDADR | UN 2811 6.1 / PGIII |